The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to remove the universal recommendation that all newborns receive the hepatitis B vaccine immediately after birth. ACIP passed the change with an 8–3 vote, directing that infants born to mothers who test negative for hepatitis B may begin the three-dose series no earlier than two months and that parents should consult clinicians about antibody testing and timing. Panel deliberations at multiple meetings exposed deep division: some ACIP members and public-health experts warned that delaying the birth dose could increase newborn vulnerability, while proponents framed the change as targeted risk-based guidance. The debate has attracted public scrutiny and commentary from immunologists and pediatric infectious-disease specialists, and the CDC typically adopts ACIP guidance, so clinical practice and state-level policy shifts may follow. ACIP also debated adjuvant safety and broader vaccine-scheduling questions at the same sessions. Reporting cited in these items includes ACIP meeting records and contemporaneous coverage from national news outlets and BioCentury.